文献速递食管胃疾病与幽门螺杆菌消化内镜

抗反流手术疗效与抑酸治疗反应在食管外反流患者中的关联

Association Between Response to Acid-Suppression Therapy and Efficacy of Antireflux Surgery in Patients With Extraesophageal Reflux.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-11-10

回顾性队列研究纳入115例接受初次抗反流手术的成人患者,其中79例为典型GERD症状、36例为食管外表现,均存在远端食管酸暴露异常。中位随访66个月,食管外症状组症状复发中位时间11.5个月,显著短于典型症状组的>132个月;术前抑酸治疗反应差与术后复发风险升高相关。

要点

  • 食管外症状是抗反流术后症状复发的独立危险因素(校正HR 2.34)。
  • 术前抑酸治疗反应差与术后复发风险升高相关(HR 3.85)。
  • 食管外症状患者中,术前抑酸治疗有部分或完全反应者术后复发率较低。

核心结论

  • 在回顾性研究中,抗反流手术对GERD食管外症状患者的疗效较典型GERD患者更难预测。
  • 术前抑酸治疗反应与食管外反流症状患者的抗反流手术疗效相关。
  • 对抑酸治疗无反应的食管外症状患者,提倡抗反流手术时应谨慎。

研究设计与样本

  • 回顾性队列研究,比较2004年至2012年在一家三级医疗中心接受初次抗反流手术的成人食管外症状与典型反流症状患者。
  • 共115例患者,其中79例为典型GERD,36例为GERD食管外表现,均有pH检测或内镜证实的远端食管酸暴露异常证据。
  • 主要结局为术后主要症状复发时间,基于随访时患者报告的部分或完全症状复发。
  • 中位随访66个月(四分位距52-77个月)。

主要发现

  • 总体队列症状复发中位时间为68个月,食管外症状组为11.5个月,典型症状组为>132个月。
  • 抗反流术后症状复发与以食管外症状为主相关(校正HR 2.34;95%CI 1.31-4.17)。
  • 抗反流术后症状复发与术前抑酸治疗症状反应差相关(HR 3.85;95%CI 2.05-7.22)。
  • 以食管外症状为主且术前抑酸治疗有完全或部分反应的患者,症状复发率低于抑酸治疗反应差的患者(P<.01)。
  • 以典型反流症状为主且术前抑酸治疗有部分或完全反应的患者,症状复发率最低(P<.01)。

关键数值与推荐

  • 食管外症状组症状复发中位时间11.5个月 vs 典型症状组>132个月。
  • 以食管外症状为主与术后症状复发的校正HR为2.34(95%CI 1.31-4.17)。
  • 术前抑酸治疗反应差与术后症状复发的HR为3.85(95%CI 2.05-7.22)。
  • 食管外症状患者中,术前抑酸治疗有完全或部分反应者症状复发率低于反应差者(P<.01)。
  • 典型反流症状患者中,术前抑酸治疗有部分或完全反应者症状复发率最低(P<.01)。

临床怎么用

  • 作者认为,对抑酸治疗无反应的食管外症状患者,提倡抗反流手术时应谨慎。
  • 术前抑酸治疗反应与食管外反流症状患者的抗反流手术疗效相关。
  • 抗反流手术对食管外症状患者的疗效较典型GERD患者更难预测。

局限性

  • 原文在结论中写明为回顾性研究。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effectiveness of antireflux surgery (ARS) varies among patients with extraesophageal manifestations of gastroesophageal reflux disease (GERD). By studying a cohort of patients with primary extraesophageal symptoms and abnormal physiologic markers for GERD, we aimed to identify factors associated with positive outcomes from surgery, and compare outcomes to those with typical esophageal manifestations of GERD. METHODS: We performed a retrospective cohort study to compare adult patients with extraesophageal and typical reflux symptoms who underwent de novo ARS from 2004 through 2012 at a tertiary care center. All 115 patients (79 with typical GERD and 36 with extraesophageal manifestations of GERD) had evidence of abnormal distal esophageal acid exposure based on pH testing or endoscopy. The principle outcome was time to primary symptom recurrence after surgery, based on patient reports of partial or total recurrence of symptoms at follow-up visits. Patients were followed up for a median duration of 66 months (interquartile range, 52-77 mo). RESULTS: The median time to recurrence of symptoms in the overall cohort was 68 months (11.5 months in the extraesophageal cohort vs >132 months in the typical cohort). Symptom recurrence after ARS was associated with having primarily extraesophageal symptoms (adjusted hazard ratio, 2.34; 95% confidence interval, 1.31-4.17) and poor preoperative symptom response to acid-suppression therapy (AST) (hazard ratio, 3.85; 95% confidence interval, 2.05-7.22). Patients with primary extraesophageal symptoms who had a full or partial preoperative AST response experienced lower rates of symptom recurrence compared to patients with poor AST response (P < .01). The rate of symptom recurrence was lowest among patients with primary typical reflux symptoms who had a partial or full symptom response to AST (P < .01). The severity of acid reflux on pH testing, symptom indices, severity of esophagitis, and hiatal hernia size were not associated with symptom response. CONCLUSIONS: In a retrospective study, we found the effectiveness of ARS to be less predictable in patients with extraesophageal symptoms of GERD than in patients with typical GERD. Response to AST before surgery was associated with ARS effectiveness in patients with extraesophageal reflux symptoms. Caution should be exercised when advocating ARS for patients with extraesophageal symptoms that do not respond to AST.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Krill JT, Naik RD, Higginbotham T, et al. Association Between Response to Acid-Suppression Therapy and Efficacy of Antireflux Surgery in Patients With Extraesophageal Reflux. Clin Gastroenterol Hepatol. 2016. PMID: 27840185. doi:10.1016/j.cgh.2016.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。